Company: RCUS
Filing Date: 2025-10-31
Form Type: 424B5
Source: 0001193125-25-260836
Chunk: 25

Company: Arcus Biosciences, Inc.
Filing Date: 2025-10-31
Form: 424B5
Chunk 25
---
 initial offering of the shares, the public offering price, concession or any other term of this offering may be changed by the representatives. The following table shows the initial public offering price, underwriting discounts and commissions and proceeds, before expenses, to us. The information assumes either no exercise or full exercise by the underwriters of their option to purchase additional shares of our common stock.

|                                        |     | Per   
 Share |        |     | Total          
 Without Option |             |     | With Option |             |
|:---------------------------------------|:----|:------|-------:|:----|:---------------|------------:|:----|:------------|------------:|
| Initial public offering price          |     | $     | 18.250 |     | $              | 250,025,000 |     | $           | 287,528,750 |
| Underwriting discounts and commissions |     | $     |  1.095 |     | $              |  15,001,500 |     | $           |  17,251,725 |
| Proceeds, before expenses, to us       |     | $     | 17.155 |     | $              | 235,023,500 |     | $           | 270,277,025 |

We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions referred to above, will be approximately $550,000. We also have agreed to reimburse the underwriters for up to $10,000 for their FINRA counsel fee. In accordance with FINRA Rule 5110, this reimbursed fee is deemed underwriting compensation for this offering. S-19

Option to Purchase Additional Shares

We have granted an option to the underwriters, exercisable for 30 days after the date of this prospectus supplement, to purchase up to 2,055,000 additional
shares at the initial public offering price, less underwriting discounts and commissions. If the underwriters exercise this option, each underwriter will be obligated, subject to the conditions contained in the underwriting agreement, to purchase a
number of additional shares proportionate to that underwriter’s initial amount reflected in the above table.

No Sales of Similar Securities

We have agreed with the underwriters, subject to certain exceptions, not to dispose of or hedge any of our common stock or securities convertible into
or exchangeable for shares of common stock during the period from the date of this prospectus supplement continuing through the date